Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Cardiologists (EU)

Articles with lock require a subscription to GLG News | Request a free trial
November 24, 2008
Rosuvastatin in CV risk reduction
Analysis of: CRESTOR Demonstrates Dramatic CV Risk Reduction in a Large Statin Outcomes Study | www.astrazeneca.com
Author: GLG Expert Contributor
Rosuvastatin, Crestor, Cardiovascular risk
November 13, 2008
Jupiter Study: impact on Rosuvastatin
Analysis of: CRESTOR Demonstrates Dramatic CV Risk Reduction in a Large Statin Outcomes Study | www.astrazeneca.com
Author: GLG Expert Contributor
Jupiter study demonstrated significant reduction of cardiovascular morbidity and mortality in patients with high hs-CRP and acceptable lipid profile. This study demonstrates that rosuvastatin might play a major role in modulating inflammation pathways predisposing to cardiovascular diseases....
June 19, 2008
Poise Trial: more challenging questions than answers
Analysis of: Higher Risk of Death and Stroke in Patients Given Beta Blockers After Non-Cardiac Surgery (POISE Trial) | pharmalive.com
Author: GLG Expert Contributor
The POISE trial showed an excess risk of stroke after general surgery, counter-balancing the beneficial effects of IV metoprolol, a betablocker, to protect the heart of a post-operative myocardial infarction. With the population ageing and the growing epidemics of risk factors for cardiovascular...
October 15, 2007
A user friendly femoral access closure device with a fast learning curve
Analysis of: St. Jude Medical Announces Japanese Approval Of The Angio-Seal STS Plus Vascular Closure Device | www.medicalnewstoday.com
Author: GLG Expert Contributor
1. Angioseal is a very user friendly closure device which saves staff time spent with the patient and reduces he number of pseudoaneurysms, but it does not reduce the overall number of bleeding complications. 2. Angioiseal will probably continue to increase its market share in centers not moving...
October 15, 2007
A new tool to improve survival rates in cardiac arrest victims?
Analysis of: Physio-Control Announces Availability Of LUCAS™ Chest Compression System In United States | www.medicalnewstoday.com
Author: GLG Expert Contributor
1. LUCAS can effectively sustain circulation in spite of cardiac arrest through external mechanical chest compressions thus maintaining a sustenance of blood flow to the brain during CPR. 2. Effective external mechanical chest compression devices like LUCAS, offer a new tool to aid in the treatment...
October 11, 2007
A New DES with less efficacy but maybe a better saftey profile is on the way.
Analysis of: FDA Panel Recommends Approval Of Medtronic Drug-Coated Stent | online.wsj.com
Author: GLG Expert Contributor
1. ENDEVOR subscribes to cardiologist concerned about the saftey profile of Current DES sold in the US (Cypher and TAXUS). 2. ENDEAVOR seems to carry a higher rate of binary restenosis than Cypher, but may have a lower rate of late stent subacute thrombosis (SAT) than either Taxus or...
July 30, 2007
Better stent technique
Analysis of: Scrutiny of Stent Problems Turns to Doctors | online.wsj.com
Author: GLG Expert Contributor
Ten years ago  before drug-eluting era, according to A. Colombo to diminish the stent restenosis three are 3 rules; balloon/artery ratio must be 1.1,  stenting with high deployment pressure and using IVUS. These recommedations are still in common use and stents...
July 11, 2007
Safety issue of Endeavor
Analysis of: Two-Year Results from the Medtronic Endeavor III Trial Confirm Stent’s Positive Clinical Profile | wwwp.medtronic.com
Author: GLG Expert Contributor
Drug eluting stens have been produced to reduce rates of stent restenosis and late lumen loss compared with bare metal stents. Mauri et al. showed there is that there is relationship between late lumen loss and stent restenosis. Head to head comparisions between Endeavor and Cypher stent have ...
January 22, 2007
Another first generation DES enters the market
Analysis of: Boston Scientific Announces First Use Of PROMUS™ Everolimus-Eluting Stent System | www.medcompare.com
Author: GLG Expert Contributor
1. The PROMUS™ platform is a first generation DES composed of a “limus” drug and a durable polymer placed on cobalt-chromium alloy stent.2. No large randomized trial data is yet available until presentation of the SPIRIT III data, a 1400 patient randomized trial.3. PROMUS™ main niche may...
December 11, 2006
Is "on label" use of DES the solution ?
Analysis of: FDA Stent Panel Agrees that Benefits of On-Label Use Outweigh Risk | www.medpagetoday.com
Author: GLG Expert Contributor
1. DES do cause a small increase in death and MI2. The risk does not level off in comparison to BMS3. DES should be used "on-label"

Page : 1 2 Next1 to 10 of 11

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T13:45:22.747